Sensei Biotherapeutics (NASDAQ:SNSE) Issues Earnings Results, Misses Estimates By $130.83 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) released its earnings results on Friday. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83), FiscalAI reports.

Sensei Biotherapeutics Trading Up 3.1%

Shares of SNSE traded up $0.61 during midday trading on Friday, reaching $20.43. The stock had a trading volume of 40,624 shares, compared to its average volume of 30,397. The firm has a 50 day simple moving average of $28.89 and a 200-day simple moving average of $17.87. Sensei Biotherapeutics has a one year low of $5.25 and a one year high of $36.76. The firm has a market cap of $27.38 million, a PE ratio of -1.23 and a beta of -0.18.

Insider Activity at Sensei Biotherapeutics

In other news, major shareholder Millennium Management Llc acquired 15,321 shares of the firm’s stock in a transaction dated Friday, March 27th. The stock was bought at an average price of $26.61 per share, with a total value of $407,691.81. Following the transaction, the insider directly owned 142,360 shares in the company, valued at approximately $3,788,199.60. The trade was a 12.06% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 46,980 shares of company stock valued at $1,341,669 and have sold 23,067 shares valued at $704,439. 23.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $40.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.